Sigma first-half profit falls
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Sigma Pharmaceuticals Ltd says it continues to operate in a challenging environment after posting a fall in first-half profit, but expects a stronger second half and will look to the new federal government to provide greater certainty in the sector including limiting further changes to the Pharmaceutical Benefits Scheme.
The group's net profit after tax attributable to members fell 37.6% to $16.3 million in the six months ended July 31, 2013, compared with $26.1 million in the previous corresponding period.
Sales revenue rose 3.1% to $1.46 billion in the half, compared with $1.42 billion in the first half of 2012.
The group paid an interim dividend of two cents per share, fully franked.
Sigma chief executive officer Mark Hooper said the group "has delivered a solid performance in a difficult trading environment with PBS growth virtually non-existent and retail conditions subdued".
He said Sigma's initiatives to grow sales include the Amcal and Guardian e-commerce platforms launched in mid-2013, and increasing the products in its private range.
The group said the sales revenue increase was achieved in a period when further PBS price reforms have been implemented by the government